In this study, we present prognostic models for patients with HER2 IHC borderline (2+) BC patients, based on the expression levels of ER, PR, Ki67, HER2, and CD8 densities in the tumor tissue assessed by DIA. This evidence concerns the gene PGR and breast cancer.